Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amicas Inc.

This article was originally published in Start Up

Executive Summary

Amicas Inc. offers a broad set of solutions for Internet-based image management, with a focus on the radiology department.

You may also be interested in...



Imaging and the Web

In the ten years or so since picture archiving and communications systems (PACS) were introduced, only 15% of hospitals in the US have implemented them in their radiology departments; the vast majority of hospitals handle most images as they have for years--on film and manually. The reasons are many, but cost is a big factor. Hospitals simply don't have money to pay for expensive PACS. A new business model, the application service provider (ASP) offers a solution. ASPs centralize alot of PACS services, serving multiple clients at once, and archiving digital images off-site at a central location. Hospitals pay on a per transaction basis and avoid the upfront costs of installing capital equipment. The web has made this possible because images can be transmitted over the Internet to off-site storage locations.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel